Company intelligence / Profile preview

ArBlast

Kobe, Hyogo, Japan

Ownership: Private
Development stage: Other

Overview

ArBlast is a Japanese biotechnology company specializing in regenerative medicine for ophthalmic diseases. The company is best known for developing cultured corneal epithelial cell sheets used to treat corneal epithelial stem cell deficiency, a condition that can lead to blindness. Founded as a venture from Kyoto Prefectural University of Medicine, ArBlast successfully brought its lead regenerative therapy, Nepic, to the Japanese market. In 2020, the company was acquired by Japan Tissue Engineering (J-TEC) to consolidate expertise in tissue-engineered products. The acquisition allowed for the integration of ArBlast's ophthalmic innovations into J-TEC's broader regenerative medicine portfolio.

Therapeutic areas: Ophthalmology
Modalities: Cell therapy
Industry: Biotech

Partnerships

Kyoto Prefectural University of Medicine

Beyond the preview

Go deeper on ArBlast.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArBlast.

Explore the full profile